Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FOLD – Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.
FOLD
$7.08
Name : Amicus Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,173,722,880.00
EPSttm : -0.18
finviz dynamic chart for FOLD
Amicus Therapeutics, Inc.
$7.08
5.67%
$0.425

Float Short %

5.88

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

0.06

EPS Last/This Y

0.69

EPS This/Next Y

0.33

Price

7.49

Target Price

16.73

Analyst Recom

1.5

Performance Q

-19.44

Relative Volume

1.26

Beta

0.63

Ticker: FOLD




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-10FOLD8.640.560.0514828
2025-03-11FOLD8.860.560.0014866
2025-03-12FOLD8.880.560.0014866
2025-03-13FOLD8.810.560.0014871
2025-03-14FOLD8.890.560.0014873
2025-03-17FOLD9.110.540.0014990
2025-03-18FOLD8.990.530.0015092
2025-03-19FOLD9.190.531.6915101
2025-03-20FOLD9.080.575.9415909
2025-03-21FOLD90.620.0016609
2025-03-24FOLD8.690.680.0015631
2025-03-25FOLD8.620.560.0317660
2025-03-26FOLD8.510.540.0018073
2025-03-27FOLD8.590.540.0018078
2025-03-28FOLD8.430.540.5018083
2025-03-31FOLD8.160.540.0018074
2025-04-01FOLD7.950.540.0018074
2025-04-02FOLD7.980.540.0018084
2025-04-03FOLD7.990.530.2518298
2025-04-04FOLD7.490.530.2518300
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-10FOLD8.64516.952.50.51
2025-03-11FOLD8.87516.956.10.51
2025-03-12FOLD8.89516.954.30.51
2025-03-13FOLD8.81516.953.50.51
2025-03-14FOLD8.90516.954.90.51
2025-03-17FOLD9.12516.956.00.51
2025-03-18FOLD8.98516.953.10.51
2025-03-19FOLD9.20516.955.90.51
2025-03-20FOLD9.08516.953.20.51
2025-03-21FOLD9.00516.953.50.51
2025-03-24FOLD8.69516.951.70.51
2025-03-25FOLD8.62516.953.60.51
2025-03-26FOLD8.52516.953.40.51
2025-03-27FOLD8.59516.954.70.51
2025-03-28FOLD8.43516.952.90.51
2025-03-31FOLD8.16516.951.90.51
2025-04-01FOLD7.95516.952.50.51
2025-04-02FOLD7.99516.954.50.51
2025-04-03FOLD8.00516.954.20.51
2025-04-04FOLD7.49516.949.80.51
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-10FOLD-0.29-1.684.97
2025-03-11FOLD-0.29-1.684.97
2025-03-12FOLD-0.29-1.685.24
2025-03-13FOLD-0.29-1.685.24
2025-03-14FOLD-0.30-1.685.24
2025-03-17FOLD-0.30-1.755.24
2025-03-18FOLD-0.30-1.755.24
2025-03-19FOLD-0.30-1.755.24
2025-03-20FOLD-0.30-1.755.24
2025-03-21FOLD-0.30-1.755.24
2025-03-24FOLD-0.30-1.755.24
2025-03-25FOLD-0.30-1.755.24
2025-03-26FOLD-0.30-1.755.88
2025-03-27FOLD-0.30-1.755.88
2025-03-28FOLD-0.30-1.755.88
2025-03-31FOLD-0.30-1.755.88
2025-04-01FOLD-0.30-1.755.88
2025-04-02FOLD-0.30-1.755.88
2025-04-03FOLD-0.30-1.755.88
2025-04-04FOLD-0.30-1.755.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.05

Avg. EPS Est. Current Quarter

0.08

Avg. EPS Est. Next Quarter

0.11

Insider Transactions

-0.3

Institutional Transactions

-1.75

Beta

0.63

Average Sales Estimate Current Quarter

136

Average Sales Estimate Next Quarter

150

Fair Value

Quality Score

51

Growth Score

54

Sentiment Score

41

Actual DrawDown %

70.5

Max Drawdown 5-Year %

-75

Target Price

16.73

P/E

Forward P/E

22.54

PEG

P/S

4.36

P/B

11.56

P/Free Cash Flow

EPS

-0.18

Average EPS Est. Cur. Y​

0.51

EPS Next Y. (Est.)

0.84

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.62

Relative Volume

1.26

Return on Equity vs Sector %

-48.7

Return on Equity vs Industry %

-35.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.13

EBIT Estimation

49.8
Amicus Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 499
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today
news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance
stock history FOLD – Amicus Therapeutics, Inc. invest stock market
stock prices FOLD premarket after hours
ticker FOLD fair value insiders trading